Completed PHASE2 INTERVENTIONAL 5-arm NCT01166061

Safety and Tolerability of ToleroMune Grass in Grass Allergic Subjects With Rhinoconjunctivitis

An Escalating, Multiple-dose Study in Grass Allergic Subjects to Assess the Safety of Intradermal Injection of ToleroMune Grass

Sponsor: Adiga Life Sciences, Inc.

Conditions Allergy

Interventions Placebo ToleroMune Grass

Updated 6 times since 2017 Last updated: May 19, 2011 Started: Jul 31, 2010 Primary completion: Apr 30, 2011 Completion: Apr 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Allergy and is currently completed. Adiga Life Sciences, Inc. leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Adiga Life Sciences, Inc.
Circassia Limited

Data source: Circassia Limited

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Québec, Canada